CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
Rhea-AI Summary
CVRx (NASDAQ: CVRX), a commercial-stage medical device company specializing in neuromodulation solutions for cardiovascular diseases, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 3:00 PM ET.
Investors and interested parties can access the live audio webcast of the presentation through the investor relations section of CVRx's website at ir.cvrx.com.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the trading session that priced this news, CVRX declined 2.02%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
